Klinická farmakologie a farmacie – 3/2018

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2019; 33(3): 29–36 /  www.klinickafarmakologie.cz 36 HLAVNÍ TÉMA Bezpečnost léčby roztroušené sklerózy z dlouhodobého hlediska ve vztahu k teriflunomidu a alemtuzumabu 19. Coles AJ, Compston DAC, Selmaj KW, et al. Alemtuzumab vs. Interferon beta‑1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–1801. 20. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab ver­ sus interferon beta 1a as first‑line treatment for patients with relapsing‑remitting multiple sclerosis: a randomised contro­ lled phase 3 trial. Lancet 2012; 380: 1819–1828. 21. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease‑mo­ difying therapy: a randomised controlled phase 3 trial. Lan­ cet 2012; 380: 1829–1839. 22. ColesAJ,CohenJA,FoxEJ,etal.CARE‑MS IIandCAMMS03409 Investigators.AlemtuzumabCARE‑MS II5‑year follow‑up:Effica­ cy and safety findings. Neurology 2017; 89: 1117–1126. 23. Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for Multiple Sclerosis. Mult Scler 2016; 22: 1215–1223. 24. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or in­ tramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415. 25. Buonomo AR, Zappulo E, Viceconte G, et al. Risk of op­ portunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018; 17: 709–717. 26. Costelloe L, Jones J, Coles A. Secondary autoimmune di­ seases following alemtuzumab therapy for multiple sclero­ sis. Expert Rev Neurother 2012; 12: 335–341. 27. ColesAJ,CohenJA,FoxEJ,etal.CARE‑MS IIandCAMMS03409 Investigators.AlemtuzumabCARE‑MS II5‑year follow‑up:Effica­ cy and safety findings. Neurology 2017; 89: 1117–1126. 28. TOPAZ: 1. Coles AJ, et al. ACTRIMS‑ECTRIMS 2017, Pos­ ter P1188; 2. Singer BV, et al. ACTRIMS‑ECTRIMS 2017, Poster P736; 3. Traboulsee A, et al. AAN 2017, P2. 104; 4. Clinical­ trials.gov. https:// clinicaltrials.gov/ct2/show/NCT02255656. Accessed September 7, 2017.